BG107891A - П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика - Google Patents
П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика Download PDFInfo
- Publication number
- BG107891A BG107891A BG107891A BG10789103A BG107891A BG 107891 A BG107891 A BG 107891A BG 107891 A BG107891 A BG 107891A BG 10789103 A BG10789103 A BG 10789103A BG 107891 A BG107891 A BG 107891A
- Authority
- BG
- Bulgaria
- Prior art keywords
- peptides
- medicament
- residue
- preparation
- apr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 123
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 71
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 65
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
- 230000000069 prophylactic effect Effects 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 8
- 150000001408 amides Chemical class 0.000 claims abstract description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 8
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 8
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 44
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 24
- 102000009123 Fibrin Human genes 0.000 claims description 22
- 229950003499 fibrin Drugs 0.000 claims description 22
- 108010073385 Fibrin Proteins 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 238000011321 prophylaxis Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 210000002889 endothelial cell Anatomy 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 11
- 230000002792 vascular Effects 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 claims description 6
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 6
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 claims description 5
- ZVYYMCXVPZEAPU-CWRNSKLLSA-N Asp-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZVYYMCXVPZEAPU-CWRNSKLLSA-N 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 108010087924 alanylproline Proteins 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 125000003158 alcohol group Chemical group 0.000 claims description 4
- 108010021908 aspartyl-aspartyl-glutamyl-aspartic acid Proteins 0.000 claims description 4
- 150000007529 inorganic bases Chemical group 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- KUBFPYIMAGXGBT-ACZMJKKPSA-N Gln-Ser-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KUBFPYIMAGXGBT-ACZMJKKPSA-N 0.000 claims description 3
- PBFGQTGPSKWHJA-QEJZJMRPSA-N Glu-Asp-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O PBFGQTGPSKWHJA-QEJZJMRPSA-N 0.000 claims description 3
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 108010077112 prolyl-proline Proteins 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims 13
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 12
- 150000002430 hydrocarbons Chemical group 0.000 claims 4
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 claims 3
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims 3
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 claims 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 claims 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 claims 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 claims 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims 1
- 108010053725 prolylvaline Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract description 3
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 108010002921 NDSK-II Proteins 0.000 description 50
- NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 description 47
- 230000005012 migration Effects 0.000 description 19
- 238000013508 migration Methods 0.000 description 19
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000001616 monocyte Anatomy 0.000 description 12
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000527 lymphocytic effect Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000208 fibrin degradation product Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 101800003778 Fibrinopeptide B Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960005051 fluostigmine Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- 241000131390 Glis Species 0.000 description 1
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000000282 fibrinogen degradation product Substances 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000026881 post-infectious disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT20632000 | 2000-12-12 | ||
| PCT/AT2001/000387 WO2002048180A2 (de) | 2000-12-12 | 2001-12-07 | Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107891A true BG107891A (bg) | 2004-08-31 |
Family
ID=3689750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107891A BG107891A (bg) | 2000-12-12 | 2003-06-09 | П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7271144B2 (es) |
| EP (2) | EP1586586B1 (es) |
| JP (1) | JP4181874B2 (es) |
| KR (1) | KR100864069B1 (es) |
| CN (2) | CN1518558B (es) |
| AT (2) | ATE329614T1 (es) |
| AU (1) | AU2002221316A1 (es) |
| BG (1) | BG107891A (es) |
| BR (1) | BR0116122A (es) |
| CA (1) | CA2430972C (es) |
| CY (2) | CY1106108T1 (es) |
| CZ (1) | CZ20031630A3 (es) |
| DE (2) | DE50114771D1 (es) |
| DK (2) | DK1341819T3 (es) |
| EA (1) | EA005576B1 (es) |
| EE (1) | EE200300283A (es) |
| ES (2) | ES2323963T3 (es) |
| HK (1) | HK1084400A1 (es) |
| HR (1) | HRP20030564A2 (es) |
| HU (1) | HUP0401536A3 (es) |
| IL (2) | IL156360A0 (es) |
| MX (1) | MXPA03005218A (es) |
| NO (1) | NO330767B1 (es) |
| NZ (1) | NZ550619A (es) |
| PL (2) | PL209752B1 (es) |
| PT (2) | PT1341819E (es) |
| SI (2) | SI1341819T1 (es) |
| SK (1) | SK7062003A3 (es) |
| WO (1) | WO2002048180A2 (es) |
| YU (1) | YU53803A (es) |
| ZA (1) | ZA200304545B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4181874B2 (ja) | 2000-12-12 | 2008-11-19 | ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー | ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用 |
| ATE439856T1 (de) * | 2004-06-25 | 2009-09-15 | Fibrex Medical Res & Dev Gmbh | Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
| FR2879604B1 (fr) * | 2004-12-22 | 2010-08-13 | Biomerieux Sa | Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations |
| AT502987A1 (de) | 2005-12-23 | 2007-07-15 | Fibrex Medical Res & Dev Gmbh | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| US8067533B2 (en) | 2006-02-23 | 2011-11-29 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| ES2371038T3 (es) | 2006-02-23 | 2011-12-26 | Fibrex Medical Research & Development Gmbh | Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos. |
| WO2007095659A1 (de) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels |
| FR2900657B1 (fr) * | 2006-05-03 | 2009-04-17 | Univ Toulouse | Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide |
| WO2009038729A2 (en) | 2007-09-17 | 2009-03-26 | Regenerx Biopharmaceuticals, Inc. | Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen |
| FR2908134B1 (fr) * | 2007-12-04 | 2012-10-12 | Univ Toulouse 3 Paul Sabatier | Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide |
| JP5410997B2 (ja) * | 2008-01-31 | 2014-02-05 | 則行 川村 | うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断 |
| US20090286725A1 (en) * | 2008-05-15 | 2009-11-19 | Fibrex Medical Research & Development Gmbh | Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| US8088890B2 (en) * | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| WO2010043444A2 (en) * | 2008-10-15 | 2010-04-22 | Fibrex Medical Research & Development Gmbh | Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof |
| US20100152832A1 (en) * | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927916A (en) | 1984-04-23 | 1990-05-22 | The General Hospital Corporation | Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides |
| US5965107A (en) * | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| DE19729591A1 (de) * | 1997-07-10 | 1999-02-11 | Therasorb Medizinische Systeme | Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen |
| FR2795735B1 (fr) * | 1999-07-01 | 2001-09-07 | Univ Toulouse | Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide |
| JP4181874B2 (ja) * | 2000-12-12 | 2008-11-19 | ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー | ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用 |
| US7201763B2 (en) | 2001-10-24 | 2007-04-10 | Boston Scientific Scimed, Inc. | Distal balloon waist material relief and method of manufacture |
-
2001
- 2001-12-07 JP JP2002549711A patent/JP4181874B2/ja not_active Expired - Fee Related
- 2001-12-07 PL PL390342A patent/PL209752B1/pl not_active IP Right Cessation
- 2001-12-07 CN CN018225993A patent/CN1518558B/zh not_active Expired - Fee Related
- 2001-12-07 AT AT01270546T patent/ATE329614T1/de active
- 2001-12-07 DE DE50114771T patent/DE50114771D1/de not_active Expired - Lifetime
- 2001-12-07 PL PL362924A patent/PL209419B1/pl not_active IP Right Cessation
- 2001-12-07 EP EP05012488A patent/EP1586586B1/de not_active Expired - Lifetime
- 2001-12-07 AT AT05012488T patent/ATE425184T1/de active
- 2001-12-07 SK SK706-2003A patent/SK7062003A3/sk unknown
- 2001-12-07 ES ES05012488T patent/ES2323963T3/es not_active Expired - Lifetime
- 2001-12-07 ES ES01270546T patent/ES2266093T3/es not_active Expired - Lifetime
- 2001-12-07 PT PT01270546T patent/PT1341819E/pt unknown
- 2001-12-07 NZ NZ550619A patent/NZ550619A/en unknown
- 2001-12-07 DE DE50110182T patent/DE50110182D1/de not_active Expired - Lifetime
- 2001-12-07 DK DK01270546T patent/DK1341819T3/da active
- 2001-12-07 DK DK05012488T patent/DK1586586T3/da active
- 2001-12-07 AU AU2002221316A patent/AU2002221316A1/en not_active Abandoned
- 2001-12-07 EA EA200300678A patent/EA005576B1/ru not_active IP Right Cessation
- 2001-12-07 CZ CZ20031630A patent/CZ20031630A3/cs unknown
- 2001-12-07 CN CN200910163553A patent/CN101676299A/zh active Pending
- 2001-12-07 YU YU53803A patent/YU53803A/sh unknown
- 2001-12-07 HU HU0401536A patent/HUP0401536A3/hu unknown
- 2001-12-07 MX MXPA03005218A patent/MXPA03005218A/es active IP Right Grant
- 2001-12-07 KR KR1020037007799A patent/KR100864069B1/ko not_active IP Right Cessation
- 2001-12-07 WO PCT/AT2001/000387 patent/WO2002048180A2/de active IP Right Grant
- 2001-12-07 SI SI200130609T patent/SI1341819T1/sl unknown
- 2001-12-07 EE EEP200300283A patent/EE200300283A/xx unknown
- 2001-12-07 BR BR0116122-9A patent/BR0116122A/pt not_active Application Discontinuation
- 2001-12-07 IL IL15636001A patent/IL156360A0/xx unknown
- 2001-12-07 CA CA2430972A patent/CA2430972C/en not_active Expired - Fee Related
- 2001-12-07 PT PT05012488T patent/PT1586586E/pt unknown
- 2001-12-07 SI SI200130917T patent/SI1586586T1/sl unknown
- 2001-12-07 EP EP01270546A patent/EP1341819B1/de not_active Expired - Lifetime
-
2003
- 2003-06-09 BG BG107891A patent/BG107891A/bg unknown
- 2003-06-09 IL IL156360A patent/IL156360A/en not_active IP Right Cessation
- 2003-06-11 US US10/459,030 patent/US7271144B2/en not_active Expired - Fee Related
- 2003-06-12 NO NO20032656A patent/NO330767B1/no not_active IP Right Cessation
- 2003-07-10 HR HR20030564A patent/HRP20030564A2/hr not_active Application Discontinuation
-
2004
- 2004-06-11 ZA ZA200304545A patent/ZA200304545B/en unknown
-
2006
- 2006-04-13 HK HK06104567.9A patent/HK1084400A1/xx not_active IP Right Cessation
- 2006-06-27 CY CY20061100876T patent/CY1106108T1/el unknown
- 2006-10-03 US US11/542,050 patent/US7494973B2/en not_active Expired - Lifetime
-
2007
- 2007-09-06 US US11/899,611 patent/US7811985B2/en not_active Expired - Fee Related
-
2008
- 2008-10-09 US US12/248,656 patent/US8067373B2/en not_active Expired - Fee Related
-
2009
- 2009-05-29 CY CY20091100574T patent/CY1109107T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7494973B2 (en) | Therapeutic fibrin-derived peptides and uses thereof | |
| AU2007219031B2 (en) | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same | |
| JP2004527469A6 (ja) | ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用 | |
| AU2007219032B2 (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| JPH083065A (ja) | 肝臓障害に対する治療剤 | |
| JP3581174B2 (ja) | 新規ペプチド並びにそれを用いた血小板凝集抑制剤、体外循環用血液凝固抑制剤及び輸血用血小板製剤保護剤 | |
| JPH10182479A (ja) | ペプチド誘導体類からなる薬剤 |